DisclosureWe earn commission on partner links; ranking is set by our published methodology — not advertisers.
Every new and pipeline GLP‑1 weight-loss drug in one place — FDA status, milestone dates, and headline trial efficacy. 3 are already FDA-approved; the rest are filed or in Phase 3. Each status and number is verified and cited.
Sorted approved first, then filed, then Phase 3. Each row shows the maker, mechanism, milestone, headline trial efficacy with the trial named, what it means for you, and a primary-source link.
Novo Nordisk · GLP-1 agonist (injection, escalated dose)
What it means: For people who tolerate the 2.4 mg dose but plateau, the 7.2 mg pen adds a measured increment of weight loss. It is an escalation, not a new molecule.
Eli Lilly · Oral non-peptide small-molecule GLP-1 agonist (once-daily pill)
What it means: The first small-molecule oral GLP-1 — chemically synthesized, so manufacturable at scale, and taken any time of day. Lower efficacy than injectables, but the easiest oral to take.
Novo Nordisk · Oral GLP-1 agonist (once-daily peptide tablet)
What it means: Same semaglutide molecule as injection Wegovy, in pill form — efficacy approaches the shot, but it requires strict empty-stomach dosing (≤4 oz water, wait 30 min).
Novo Nordisk · Amylin analog (cagrilintide) + GLP-1 agonist (semaglutide)
What it means: First once-weekly amylin + GLP-1 combination. Adds a genuinely new satiety mechanism (amylin) on top of semaglutide. Would be Novo’s flagship answer to tirzepatide.
Eli Lilly · Triple agonist: GLP-1 + GIP + glucagon receptor (weekly injection)
What it means: The new efficacy ceiling if approved. The glucagon arm also targets liver fat (MASH). Not available outside trials — do not delay current treatment waiting for it.
Boehringer Ingelheim / Zealand Pharma · GLP-1 + glucagon dual agonist (weekly injection)
What it means: The leading dual-agonist for obesity plus diagnosed fatty-liver disease (MASH). The glucagon arm specifically mobilizes liver fat — a differentiation tirzepatide does not emphasize.
Innovent Biologics (licensed from Eli Lilly) · GLP-1 + glucagon dual agonist (weekly injection)
What it means: A signal of where dual-agonist development is heading and the first China-developed GLP-1/glucagon agonist. US patients have no near-term access route.
The regulatory events that moved this board — pulled from our dated GLP-1 changelog, newest first.
Eli Lilly topline Phase 3 data: 28.3% average body weight loss at 80 weeks on 12 mg, up to 30.3% in higher-BMI cohorts, the deepest of any GLP-1-class drug. NDA expected end of 2026.
Retatrutide deep-dive →FDA expanded oral semaglutide availability through Weight Watchers Med+, broadening the oral T2D dispensing landscape. See our oral GLP-1 hub.
Oral GLP-1 hub →Real-world data confirms high discontinuation — around two-thirds of people without diabetes stop within a year. The twist: far fewer actually restart (about a third) than say they will. This cycling behaviour is the subject of our lifecycle hub.
GLP-1 lifecycle →Eli Lilly’s first small-molecule oral GLP-1, approved for chronic weight management — no food/water timing restrictions; manufacturable at scale. ~12.4% mean weight loss at 72 weeks (ATTAIN-1). Type 2 diabetes filing expected 2026.
Oral GLP-1 hub →Higher-dose Wegovy approved for adults who tolerate 2.4 mg but plateau. STEP UP trial showed ~5-6 percentage points additional weight loss.
Wegovy HD →As of June 2026, three are FDA-approved for weight management: the Wegovy pill (oral semaglutide 25 mg, available January 2026), Foundayo (orforglipron, the first small-molecule oral GLP-1, approved April 1, 2026), and Wegovy HD (semaglutide 7.2 mg, approved March 19, 2026). Foundayo and the Wegovy pill are oral; Wegovy HD is a higher-dose injection.
Novo Nordisk submitted CagriSema (cagrilintide + semaglutide) to the FDA on December 18, 2025, and a review is expected during 2026. The FDA has not published a decision date, so any specific approval date would be speculation. REDEFINE-1 showed about 22.7% weight loss at 68 weeks.
No. Retatrutide (Eli Lilly’s triple agonist) is in Phase 3. TRIUMPH-1 topline data reported May 21, 2026 showed 28.3% mean weight loss at 80 weeks — the deepest of any GLP-1-class drug — but an FDA filing is only expected by end of 2026, with possible approval in 2027. It is not available outside clinical trials.
Generally no. Filing and approval timelines shift, and investigational drugs are not available outside trials. Clinicians broadly advise not delaying an approved, effective treatment to wait for a pipeline agent. Use this tracker to plan future switches, not to postpone care.
The efficacy figures are average percent body-weight loss at each trial’s primary endpoint. Real-world results typically run lower than trial averages because of adherence and dose-escalation differences. Always read the figure alongside the named trial and the linked source.
Editorial status tracker of investigational and newly approved drugs. Phase progression, trial readouts, and FDA timelines change; this is not a regulatory filing schedule and not medical advice. Each status, date, and efficacy figure is linked to a primary source above. Verified by LoseLab editorial June 2026.